Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.
Identification of each animal in a collective becomes possible even when individuals are never all visible simultaneously, enabling faster and more accurate analysis of collective behavior.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results